Moutaz W. Sweileh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Moutaz W. Sweileh has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Hisham Asaad
2 shared publicationsNaim Qamhia
Department of Pathology & Laboratory Medicine, Royal Liverpool University Hospital, Liverpool, UK, nhs.uk
2 shared publicationsAmal Batta
Department of Pathology, An-Najah National University Hospital, Nablus, State of Palestine, najah.edu
1 shared publicationAya Abdi
1 shared publication- Dina Abugaber
Department of Medicine, Faculty of Medicine and Allied Medical Sciences An‐Najah National University Nablus Palestine
1 shared publication - Halla Albada
Department of Medicine, Faculty of Medicine and Allied Medical Sciences An‐Najah National University Nablus Palestine
1 shared publication
Latest Publications
- Open Access
- 28 September 2026
- Published by Springer Nature in Cureus
- Vol. 18 (9)
Combined Vitamin B12 and Folate Deficiency Presenting As Pseudo-Thrombotic Microangiopathy With a Disseminated Intravascular Coagulation (DIC)-Like Coagulation Profile: A Case Report
Severe vitamin B12 deficiency can rarely present as pseudo-thrombotic microangiopathy (pseudo-TMA), characterized by anemia, thrombocytopenia, biochemical hemolysis, and schistocytosis, thereby mimicking thrombotic thrombocytopenic purpura (TTP). Concomitant abnormalities of conventional coagulation parameters may further complicate the presentation by raising concern for disseminated intravascular coagulation (DIC). We report an unusual presentation of severe combined vitamin B12 and folate deficiency with pseudo-TMA and a DIC-like coagulation profile. A 56-year-old man with severe combined vitamin B12 and folate deficiency presented with profound pancytopenia, schistocytosis, biochemical hemolysis, inadequate reticulocytosis, and megaloblastic hematopoiesis despite normal mean corpuscular volume (MCV). Elevated D-dimer, prolonged prothrombin time (PT), and reduced fibrinogen produced a DIC-like profile. Hematologic and coagulation parameters improved within one week of starting vitamin B12 replacement; folic acid was initiated after that first week. Recognition of megaloblastic pseudo-TMA and its potential coagulation abnormalities may prevent misdiagnosis and unnecessary TTP-directed therapy.
- 28 September 2026
- Published by Springer Nature in Cureus
- Vol. 18 (9)
Open AccessCombined Vitamin B12 and Folate Deficiency Presenting As Pseudo-Thrombotic Microangiopathy With a Disseminated Intravascular Coagulation (DIC)-Like Coagulation Profile: A Case Report
Severe vitamin B12 deficiency can rarely present as pseudo-thrombotic microangiopathy (pseudo-TMA), characterized by anemia, thrombocytopenia, biochemical hemolysis, and schistocytosis, thereby mimicking thrombotic thrombocytopenic purpura (TTP). Concomitant abnormalities of conventional coagulation parameters may further complicate the presentation by raising concern for disseminated intravascular coagulation (DIC). We report an unusual presentation of severe combined vitamin B12 and folate deficiency with pseudo-TMA and a DIC-like coagulation profile. A 56-year-old man with severe combined vitamin B12 and folate deficiency presented with profound pancytopenia, schistocytosis, biochemical hemolysis, inadequate reticulocytosis, and megaloblastic hematopoiesis despite normal mean corpuscular volume (MCV). Elevated D-dimer, prolonged prothrombin time (PT), and reduced fibrinogen produced a DIC-like profile. Hematologic and coagulation parameters improved within one week of starting vitamin B12 replacement; folic acid was initiated after that first week. Recognition of megaloblastic pseudo-TMA and its potential coagulation abnormalities may prevent misdiagnosis and unnecessary TTP-directed therapy.
- Open Access
- 2 September 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (9)
Knowledge, Attitudes, and Practices Regarding Intravenous Fluids Among Physicians in the West Bank of Palestine: A Cross‐Sectional Study
Background and Aims: Inappropriate use of intravenous (IV) fluids is associated with increased morbidity. Despite their routine use in hospitalized patients, physicians' knowledge, attitudes, and practices (KAP) regarding IV fluids remain inadequately investigated. This study assessed physicians' KAP in the West Bank, Palestine. Methods: A cross‐sectional online survey targeted physicians caring for hospitalized adult patients in West Bank hospitals. A questionnaire assessed demographic and professional characteristics, knowledge, attitudes, practices, and perceived barriers regarding IV fluids. Knowledge scores were converted into percentages and summarized using medians/interquartile ranges (IQR). Comparison of knowledge scores across physician subgroups was performed using the Mann–Whitney U test and the Kruskal–Wallis test, with Dunn's post hoc test and a Holm adjustment where appropriate. Attitudes, practices, and perceived barriers were presented as frequencies and percentages. Results: Of 256 participants (median age = 28 years, IQR 25–33), there were 173 (67.6%) males and 72 (28.1%) reported receiving formal IV fluids training during the previous 2 years. Residents and fellows comprised 101 (39.5%). The median knowledge score was 57.7% (IQR 35.7). The highest correct response in the knowledge section ( n = 223, 87.1%) was observed for identifying hyperchloremic metabolic acidosis as a complication of 0.9% saline, while the lowest correct response ( n = 67, 26.2%) was observed for identifying IV fluids not recommended for routine use. Knowledge scores differed significantly by departmental affiliation ( P < 0.001) and professional position status ( P = 0.03). Regarding attitudes, 116 (45%) agreed/strongly agreed that balanced crystalloids should be preferred over 0.9% saline in most ICU patients. In practice, 140 (54.7%) reported using 0.9% saline as the first‐line fluid in their practice. The most cited barrier was the absence of institutional guidelines ( n = 157, 61.3%). Conclusion: Physicians demonstrated average knowledge, suboptimal practices, and limited agreement with evidence‐based attitudes toward IV fluid therapy. Educational interventions and hospital protocols are needed to help improve KAP.
- 2 September 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (9)
Open AccessKnowledge, Attitudes, and Practices Regarding Intravenous Fluids Among Physicians in the West Bank of Palestine: A Cross‐Sectional Study
Background and Aims: Inappropriate use of intravenous (IV) fluids is associated with increased morbidity. Despite their routine use in hospitalized patients, physicians' knowledge, attitudes, and practices (KAP) regarding IV fluids remain inadequately investigated. This study assessed physicians' KAP in the West Bank, Palestine. Methods: A cross‐sectional online survey targeted physicians caring for hospitalized adult patients in West Bank hospitals. A questionnaire assessed demographic and professional characteristics, knowledge, attitudes, practices, and perceived barriers regarding IV fluids. Knowledge scores were converted into percentages and summarized using medians/interquartile ranges (IQR). Comparison of knowledge scores across physician subgroups was performed using the Mann–Whitney U test and the Kruskal–Wallis test, with Dunn's post hoc test and a Holm adjustment where appropriate. Attitudes, practices, and perceived barriers were presented as frequencies and percentages. Results: Of 256 participants (median age = 28 years, IQR 25–33), there were 173 (67.6%) males and 72 (28.1%) reported receiving formal IV fluids training during the previous 2 years. Residents and fellows comprised 101 (39.5%). The median knowledge score was 57.7% (IQR 35.7). The highest correct response in the knowledge section ( n = 223, 87.1%) was observed for identifying hyperchloremic metabolic acidosis as a complication of 0.9% saline, while the lowest correct response ( n = 67, 26.2%) was observed for identifying IV fluids not recommended for routine use. Knowledge scores differed significantly by departmental affiliation ( P < 0.001) and professional position status ( P = 0.03). Regarding attitudes, 116 (45%) agreed/strongly agreed that balanced crystalloids should be preferred over 0.9% saline in most ICU patients. In practice, 140 (54.7%) reported using 0.9% saline as the first‐line fluid in their practice. The most cited barrier was the absence of institutional guidelines ( n = 157, 61.3%). Conclusion: Physicians demonstrated average knowledge, suboptimal practices, and limited agreement with evidence‐based attitudes toward IV fluid therapy. Educational interventions and hospital protocols are needed to help improve KAP.
- Open Access
- 27 April 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (4)
Knowledge mapping and bibliometric insights of scientific research on targeted protein degradation in oncology
Disruption of cellular proteostasis leads to the accumulation and persistence of pathogenic proteins that drive oncogenesis. Key oncogenic and tumor suppressor proteins are frequently dysregulated in cancer, yet remain challenging to target by conventional small-molecule inhibitors. Targeted protein degradation (TPD), particularly through Proteolysis Targeting Chimeras (PROTACs) and molecular glues, has emerged as a transformative strategy that enables catalytic and selective elimination of disease-driving proteins. This study aimed to systematically map the global scientific landscape of TPD research in oncology using bibliometric methods. A comprehensive bibliometric analysis was conducted using the Scopus database covering articles published between January 2000 and December 2025. Bibliometric indicators including publication trends, compound annual growth rate (CAGR), citations, H-index, authorship pattern, and institutional contributions were analyzed. Network visualization of keyword co-occurrence, chronological evolution, and international collaboration were performed using VOSviewer. A total of 1334 publications were identified, demonstrating exponential growth, particularly after 2018, with a CAGR of 51.9% (2016–2025). The field is highly interdisciplinary, dominated by biochemistry, pharmacology, and chemistry. The dataset exhibited a high H-index (111), reflecting rapid intellectual maturation. Authorship analysis revealed a median of 10 authors per article, underscoring extensive collaboration. China and the United States emerged as dominant contributors, forming central hubs in the global research network. PROTAC technology represented the primary research focus, with strong association to ubiquitin–proteasome mechanisms and oncogenic targets such as BRD4, MYC, androgen receptor, and estrogen receptor. Highly cited articles were predominantly methodological, highlighting foundational advances in degrader design and mechanism. TPD research is rapidly evolving toward clinically driven innovations with emerging focus on advanced delivery systems, lysosome-targeting strategies, next-generation degrader design strategies, and combination therapies to overcome pharmacokinetic and therapeutic limitations. TPD research in oncology is undergoing rapid expansion and transitioning from conceptual innovation to translational application. PROTACs dominate the field due to their modularity and catalytic efficiency, although challenges remain, including pharmacokinetic limitations, restricted E3 ligase diversity, and potential resistance mechanisms. Overall, TPD represents a paradigm shift toward event-driven pharmacology with significant potential to transform precision oncology by enabling the therapeutic elimination of previously intractable targets. The online version contains supplementary material available at 10.1007/s00432-026-06482-0.
- 27 April 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (4)
Open AccessKnowledge mapping and bibliometric insights of scientific research on targeted protein degradation in oncology
Disruption of cellular proteostasis leads to the accumulation and persistence of pathogenic proteins that drive oncogenesis. Key oncogenic and tumor suppressor proteins are frequently dysregulated in cancer, yet remain challenging to target by conventional small-molecule inhibitors. Targeted protein degradation (TPD), particularly through Proteolysis Targeting Chimeras (PROTACs) and molecular glues, has emerged as a transformative strategy that enables catalytic and selective elimination of disease-driving proteins. This study aimed to systematically map the global scientific landscape of TPD research in oncology using bibliometric methods. A comprehensive bibliometric analysis was conducted using the Scopus database covering articles published between January 2000 and December 2025. Bibliometric indicators including publication trends, compound annual growth rate (CAGR), citations, H-index, authorship pattern, and institutional contributions were analyzed. Network visualization of keyword co-occurrence, chronological evolution, and international collaboration were performed using VOSviewer. A total of 1334 publications were identified, demonstrating exponential growth, particularly after 2018, with a CAGR of 51.9% (2016–2025). The field is highly interdisciplinary, dominated by biochemistry, pharmacology, and chemistry. The dataset exhibited a high H-index (111), reflecting rapid intellectual maturation. Authorship analysis revealed a median of 10 authors per article, underscoring extensive collaboration. China and the United States emerged as dominant contributors, forming central hubs in the global research network. PROTAC technology represented the primary research focus, with strong association to ubiquitin–proteasome mechanisms and oncogenic targets such as BRD4, MYC, androgen receptor, and estrogen receptor. Highly cited articles were predominantly methodological, highlighting foundational advances in degrader design and mechanism. TPD research is rapidly evolving toward clinically driven innovations with emerging focus on advanced delivery systems, lysosome-targeting strategies, next-generation degrader design strategies, and combination therapies to overcome pharmacokinetic and therapeutic limitations. TPD research in oncology is undergoing rapid expansion and transitioning from conceptual innovation to translational application. PROTACs dominate the field due to their modularity and catalytic efficiency, although challenges remain, including pharmacokinetic limitations, restricted E3 ligase diversity, and potential resistance mechanisms. Overall, TPD represents a paradigm shift toward event-driven pharmacology with significant potential to transform precision oncology by enabling the therapeutic elimination of previously intractable targets. The online version contains supplementary material available at 10.1007/s00432-026-06482-0.
- Open Access
- 3 April 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Global scientific growth and thematic development of spatial transcriptomics in oncology research
Background Spatial transcriptomics (ST) is a rapidly transforming cancer research by enabling spatially resolved gene expression profiling within intact tissues. However, the growth, structure, and thematic evolution of research on ST research in oncology have not been comprehensively mapped. Objective This study aims to map and analyze global research trends of ST in oncology, identifying key contributors, collaborations, thematic focus areas, and technological evolutions in the field. Method A bibliometric analysis was conducted using data extracted from Scopus database. VOSviewer tool was used to construct knowledge maps reflecting thematic clusters and intellectual clusters in ST-oncology research. Quantitative indicators were evaluated to identify historical evolution, key players, and research hotspots. Results The study identified 987 publications on ST in oncology. The annual growth of publications showed a significant surge over the past five years. China and the United States emerged as leading contributors with high levels of intra- and inter-national collaboration. Key journals included Nature Communications and Frontiers in Immunology. Academic and research institutions based in China dominated the field. Co-occurrence mapping identified the following high-frequency keywords: “tumor microenvironment”, “single-cell RNA sequencing”, and spatial resolution suggesting strong emphasis on integrating spatial biology with precision oncology. Bibliographic coupling illustrated a clustering around barcoding technologies and immune-oncology interfaces. The overlay visualization suggested a shift toward high resolution imaging, multi-omics integration, and AI-supported analytics. Conclusion ST-oncology research is expanding rapidly with clear shifts toward higher resolution and integrative analytical frameworks. These findings provide a structured overview of the field’s knowledge base and can inform researchers, funders, and stakeholders about leading about leading contributors and emerging directions.
- 3 April 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessGlobal scientific growth and thematic development of spatial transcriptomics in oncology research
Background Spatial transcriptomics (ST) is a rapidly transforming cancer research by enabling spatially resolved gene expression profiling within intact tissues. However, the growth, structure, and thematic evolution of research on ST research in oncology have not been comprehensively mapped. Objective This study aims to map and analyze global research trends of ST in oncology, identifying key contributors, collaborations, thematic focus areas, and technological evolutions in the field. Method A bibliometric analysis was conducted using data extracted from Scopus database. VOSviewer tool was used to construct knowledge maps reflecting thematic clusters and intellectual clusters in ST-oncology research. Quantitative indicators were evaluated to identify historical evolution, key players, and research hotspots. Results The study identified 987 publications on ST in oncology. The annual growth of publications showed a significant surge over the past five years. China and the United States emerged as leading contributors with high levels of intra- and inter-national collaboration. Key journals included Nature Communications and Frontiers in Immunology. Academic and research institutions based in China dominated the field. Co-occurrence mapping identified the following high-frequency keywords: “tumor microenvironment”, “single-cell RNA sequencing”, and spatial resolution suggesting strong emphasis on integrating spatial biology with precision oncology. Bibliographic coupling illustrated a clustering around barcoding technologies and immune-oncology interfaces. The overlay visualization suggested a shift toward high resolution imaging, multi-omics integration, and AI-supported analytics. Conclusion ST-oncology research is expanding rapidly with clear shifts toward higher resolution and integrative analytical frameworks. These findings provide a structured overview of the field’s knowledge base and can inform researchers, funders, and stakeholders about leading about leading contributors and emerging directions.
- Open Access
- 23 January 2026
- Published by SAGE Publications in Sage Open
- Vol. 16 (1)
Bibliometric Insights into CRISPR-Cas9 Research Targeting Human Disease Pathology
CRISPR-Cas9 has rapidly emerged as a transformative genome editing platform. To analyze and map scientific research on CRISPR-Cas9 in the context of human disease pathology. A bibliometric study was conducted on original research articles indexed in Scopus between 2010 and 2024, focused on CRISPR-Cas9 applications in human disease pathology. A total of 4,313 publications were identified with an average annual growth rate of 54.5% and an H-index of 146. The top publishing journals were Scientific Reports, International Journal of Molecular Sciences , and Nature Communications. The United States led with 1,727 articles, followed by China ( n = 1,355), with 50.9% international collaboration for the United States versus 34.4% for China. The average number of authors per article was 10.8. The top-cited article reported on CRISPR-Cas9 therapy for beta-thalassemia and sickle cell disease, followed by major studies on cystic fibrosis, amyloidosis, muscular dystrophy, and colorectal cancer. The following research themes were identified: (1) cancer pathways and metastasis (2) viral genome targeting; (3) mutation-driven genetic disorders; and (4) hematological disorders. VOSviewer maps indicated that off-target effects, delivery methods, and ethical concerns are major challenges for CRISPR-Cas9 use in human diseases. The analysis reflects exponential scientific growth and translational momentum. Future research will require refined delivery strategies, safety optimization, and ethical integration to fully harness CRISPR-Cas9’s clinical potential. Clinical Trial Registration : Not applicable.
- 23 January 2026
- Published by SAGE Publications in Sage Open
- Vol. 16 (1)
Open AccessBibliometric Insights into CRISPR-Cas9 Research Targeting Human Disease Pathology
CRISPR-Cas9 has rapidly emerged as a transformative genome editing platform. To analyze and map scientific research on CRISPR-Cas9 in the context of human disease pathology. A bibliometric study was conducted on original research articles indexed in Scopus between 2010 and 2024, focused on CRISPR-Cas9 applications in human disease pathology. A total of 4,313 publications were identified with an average annual growth rate of 54.5% and an H-index of 146. The top publishing journals were Scientific Reports, International Journal of Molecular Sciences , and Nature Communications. The United States led with 1,727 articles, followed by China ( n = 1,355), with 50.9% international collaboration for the United States versus 34.4% for China. The average number of authors per article was 10.8. The top-cited article reported on CRISPR-Cas9 therapy for beta-thalassemia and sickle cell disease, followed by major studies on cystic fibrosis, amyloidosis, muscular dystrophy, and colorectal cancer. The following research themes were identified: (1) cancer pathways and metastasis (2) viral genome targeting; (3) mutation-driven genetic disorders; and (4) hematological disorders. VOSviewer maps indicated that off-target effects, delivery methods, and ethical concerns are major challenges for CRISPR-Cas9 use in human diseases. The analysis reflects exponential scientific growth and translational momentum. Future research will require refined delivery strategies, safety optimization, and ethical integration to fully harness CRISPR-Cas9’s clinical potential. Clinical Trial Registration : Not applicable.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Hematology
- Vol. 2026 (1) , 5531249
Synchronous Presentation of Chronic Myelomonocytic Leukemia and Multiple Myeloma in a Treatment‐Naïve Patient
Background: Chronic myelomonocytic leukemia (CMML) is a clonal myelodysplastic/myeloproliferative neoplasm characterized by persistent peripheral blood monocytosis and dysplastic bone marrow morphology. Multiple myeloma (MM) is a plasma cell malignancy defined by clonal plasma cell proliferation and myeloma‐defining events. The synchronous occurrence of CMML and MM is exceptionally rare, particularly in treatment‐naïve and relatively young patients. Case Presentation: We present a 42‐year‐old‐male presenting with progressive fatigue and leukocytosis. Laboratory evaluation revealed marked absolute monocytosis (16.4 × 10 9 /L), anemia, and neutropenia. Bone marrow examination demonstrated an expanded abnormal monocytic population, further confirmed by multiparametric flow cytometry. Conventional cytogenetic analysis revealed monosomy 7, supporting the presence of a clonal myeloid neoplasm consistent with CMML. Concurrently, bone marrow biopsy showed 10%–15% plasma cells. Serum protein electrophoresis identified an IgG kappa monoclonal paraprotein (3.5 g/dL), and imaging showed a lytic bone lesion and biopsy‐provided extramedullary plasmacytoma, meeting the diagnostic criteria of symptomatic MM. The patient has no prior exposure to cytotoxic therapy. He received one cycle of azacitidine with subsequent worsening cytopenias, underscoring therapeutic complexity. Conclusions: This case describes a rare concurrent presentation of CMML and MM in a young, treatment‐naïve patient. The combination of persistent monocytosis, dysplastic marrow findings, and monosomy 7 supported the presence of clonal myeloid process coexisting with plasma cell myeloma. Recognizing concurrent hematologic malignancies is essential, as diagnostic overlap and treatment interactions present substantial management challenges. Additional molecular characterization of similar cases may elucidate potential pathogenetic connections and guide tailored therapeutic approaches.
- 1 January 2026
- Published by Wiley in Case Reports in Hematology
- Vol. 2026 (1) , 5531249
Open AccessSynchronous Presentation of Chronic Myelomonocytic Leukemia and Multiple Myeloma in a Treatment‐Naïve Patient
Background: Chronic myelomonocytic leukemia (CMML) is a clonal myelodysplastic/myeloproliferative neoplasm characterized by persistent peripheral blood monocytosis and dysplastic bone marrow morphology. Multiple myeloma (MM) is a plasma cell malignancy defined by clonal plasma cell proliferation and myeloma‐defining events. The synchronous occurrence of CMML and MM is exceptionally rare, particularly in treatment‐naïve and relatively young patients. Case Presentation: We present a 42‐year‐old‐male presenting with progressive fatigue and leukocytosis. Laboratory evaluation revealed marked absolute monocytosis (16.4 × 10 9 /L), anemia, and neutropenia. Bone marrow examination demonstrated an expanded abnormal monocytic population, further confirmed by multiparametric flow cytometry. Conventional cytogenetic analysis revealed monosomy 7, supporting the presence of a clonal myeloid neoplasm consistent with CMML. Concurrently, bone marrow biopsy showed 10%–15% plasma cells. Serum protein electrophoresis identified an IgG kappa monoclonal paraprotein (3.5 g/dL), and imaging showed a lytic bone lesion and biopsy‐provided extramedullary plasmacytoma, meeting the diagnostic criteria of symptomatic MM. The patient has no prior exposure to cytotoxic therapy. He received one cycle of azacitidine with subsequent worsening cytopenias, underscoring therapeutic complexity. Conclusions: This case describes a rare concurrent presentation of CMML and MM in a young, treatment‐naïve patient. The combination of persistent monocytosis, dysplastic marrow findings, and monosomy 7 supported the presence of clonal myeloid process coexisting with plasma cell myeloma. Recognizing concurrent hematologic malignancies is essential, as diagnostic overlap and treatment interactions present substantial management challenges. Additional molecular characterization of similar cases may elucidate potential pathogenetic connections and guide tailored therapeutic approaches.
- Open Access
- 1 December 2025
- Published by An-Najah National University in Palestinian Medical and Pharmaceutical Journal
- Vol. 11 (4)
Metastatic B2 Thymoma in a Patient with Myasthenia Gravis Presenting as a Peri-splenic Mass: A Rare Case Report
Background: Thymomas are rare epithelial tumors of the thymus. Extra-thoracic metastasis is exceptional and typically involves the liver, bone, or soft tissues. Peri-splenic recurrence is exceedingly rare. Case presentation: A 42-year-old female previously treated for thymoma and pleural metastases presented six years later with a peri-splenic mass. CT-guided core biopsy and immunohistochemistry (p40, Pan-CK, TdT, CD3) confirmed metastatic B2 thymoma. Conclusion: This case highlights an unusual pattern of abdominal recurrence and underscores the value of immunohistochemistry in differentiating thymoma metastasis from lymphoma.
- 1 December 2025
- Published by An-Najah National University in Palestinian Medical and Pharmaceutical Journal
- Vol. 11 (4)
Open AccessMetastatic B2 Thymoma in a Patient with Myasthenia Gravis Presenting as a Peri-splenic Mass: A Rare Case Report
Background: Thymomas are rare epithelial tumors of the thymus. Extra-thoracic metastasis is exceptional and typically involves the liver, bone, or soft tissues. Peri-splenic recurrence is exceedingly rare. Case presentation: A 42-year-old female previously treated for thymoma and pleural metastases presented six years later with a peri-splenic mass. CT-guided core biopsy and immunohistochemistry (p40, Pan-CK, TdT, CD3) confirmed metastatic B2 thymoma. Conclusion: This case highlights an unusual pattern of abdominal recurrence and underscores the value of immunohistochemistry in differentiating thymoma metastasis from lymphoma.
- Open Access
- 4 November 2025
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-16
Knowledge mapping and bibliometric insights into gene therapy for rare inherited hematologic pathologies: focus on sickle cell disease, hemophilia, and thalassemia
Background: Inherited hematologic disorders such as sickle cell disease (SCD), thalassemia, and hemophilia are rare but devastating conditions with high morbidity and mortality. Advances in gene therapy have opened curative prospects. The objective of the current study was to provide a comprehensive bibliometric and knowledge-mapping analysis of global research on gene therapy targeting SCD, thalassemia, and hemophilia. Methods: A Scopus-based bibliometric search was conducted for the period from 1986 to 2024. The search used title-specific queries for the target diseases and title-abstract queries for gene therapy technologies. Bibliometric indicators and network visualization maps, created by VOSviewer, were presented. Results: A total of 1399 articles were retrieved. Publication growth revealed two phases: a steady, but slow phase (1986–2018), and mature expansion phase (2019–2024), with an average annual growth rate of 28% over the last decade. The articles had a mean of 47.6 citations/article and an H-index of 126. Research was mainly distributed across medicine (39.5%), biochemistry/genetics/molecular biology (30.7%), immunology (8.1%), and pharmacology/toxicology (7.5%), reflecting the multidisciplinary nature of the field. The most prolific journal was Blood (8.6%), followed by Hemophilia , Molecular Therapy , Human Gene Therapy , and Blood Advances . The United Stated dominated the field (n = 863; 61.7%), followed by China and the United Kingdom, with the United States showing strong intra-country collaborations, while European countries demonstrated high international collaborations, often with the United States. Leading institutions included the Children’s Hospital of Philadelphia (7.5%) and University of Pennsylvania (5.9%). Co-authorship analysis revealed robust collaboration networks, with notable clusters around AAV-based hemophilia therapy and CRISPR-mediated gene correction for hemoglobinopathies. Keyword co-occurrence highlighted themes like AAV vectors, genome editing, CRISPR-Case9, and ex vivo hematopoietic stem cell modification. Overlay visualization maps indicated a recent surge in CRISPR and clinical applications research. Conclusions: The bibliometric findings underscore the rapid evolution of gene therapy research for SCD, thalassemia, and hemophilia, moving from experimental approaches to clinical translation. The strong interdisciplinary collaboration, rising clinical trials, and emergence of genome editing tools suggest that the field is entering a transformative era, offering real-world therapeutic solutions for previously incurable inherited blood disorders.
- 4 November 2025
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-16
Open AccessKnowledge mapping and bibliometric insights into gene therapy for rare inherited hematologic pathologies: focus on sickle cell disease, hemophilia, and thalassemia
Background: Inherited hematologic disorders such as sickle cell disease (SCD), thalassemia, and hemophilia are rare but devastating conditions with high morbidity and mortality. Advances in gene therapy have opened curative prospects. The objective of the current study was to provide a comprehensive bibliometric and knowledge-mapping analysis of global research on gene therapy targeting SCD, thalassemia, and hemophilia. Methods: A Scopus-based bibliometric search was conducted for the period from 1986 to 2024. The search used title-specific queries for the target diseases and title-abstract queries for gene therapy technologies. Bibliometric indicators and network visualization maps, created by VOSviewer, were presented. Results: A total of 1399 articles were retrieved. Publication growth revealed two phases: a steady, but slow phase (1986–2018), and mature expansion phase (2019–2024), with an average annual growth rate of 28% over the last decade. The articles had a mean of 47.6 citations/article and an H-index of 126. Research was mainly distributed across medicine (39.5%), biochemistry/genetics/molecular biology (30.7%), immunology (8.1%), and pharmacology/toxicology (7.5%), reflecting the multidisciplinary nature of the field. The most prolific journal was Blood (8.6%), followed by Hemophilia , Molecular Therapy , Human Gene Therapy , and Blood Advances . The United Stated dominated the field (n = 863; 61.7%), followed by China and the United Kingdom, with the United States showing strong intra-country collaborations, while European countries demonstrated high international collaborations, often with the United States. Leading institutions included the Children’s Hospital of Philadelphia (7.5%) and University of Pennsylvania (5.9%). Co-authorship analysis revealed robust collaboration networks, with notable clusters around AAV-based hemophilia therapy and CRISPR-mediated gene correction for hemoglobinopathies. Keyword co-occurrence highlighted themes like AAV vectors, genome editing, CRISPR-Case9, and ex vivo hematopoietic stem cell modification. Overlay visualization maps indicated a recent surge in CRISPR and clinical applications research. Conclusions: The bibliometric findings underscore the rapid evolution of gene therapy research for SCD, thalassemia, and hemophilia, moving from experimental approaches to clinical translation. The strong interdisciplinary collaboration, rising clinical trials, and emergence of genome editing tools suggest that the field is entering a transformative era, offering real-world therapeutic solutions for previously incurable inherited blood disorders.
- Open Access
- 3 August 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-19
Knowledge-map and bibliometric analysis of scientific research on FDA-approved Chimeric Antigen Receptor T cell products (2015–2024)
Background Chimeric Antigen Receptor T cell (CAR-T) therapy is a groundbreaking, personalized immunotherapy that genetically engineers patient or donor-derived T cells to recognize and eliminate cancer cells. The U.S FDA has approved six CAR-T cell products in the past decade. Objective Given their clinical success and scientific novelty, this study aimed to map the research landscape surrounding the FDA-approved CAR-T cell therapies using bibliometric and knowledge mapping analysis. Methods A comprehensive title/abstract search was conducted in Scopus database for documents published between 2015 and 2024. The search terms included generic, trade, and abbreviated names of all FDA-approved CAR-T cell products. Bibliometric indicators including average annual growth rate, citation impact, key contributors, authorship pattern, and international collaboration were assessed. Visualization maps of co-authorship and keyword co-occurrence were generated using VOSviewer. Results A total of 1163 documents were retrieved, with an average annual growth rate of 63.4%. Tisa-cel and axi-cel dominated the literature with 51.7% (n = 601) and 554 (47.6%) publications respectively. Ide-cel appeared in 152 (13.1%) publications, liso-cel in 125 (10.7%), and cilta-cel in 120 (10.3%). Brexu-cel was the least represented with 106 (9.1%) publications. The retrieved publications received 57,097 citations (mean = 49.1 citations per article; H-index = 103). Hematology and oncology-related journals were most prolific. The United States led global research output with 694 (59.7%) publications. Research output from European countries showed strong dependence on U.S.-based partnerships. Institutionally, the University of Texas MD Anderson Cancer Center, with 132 publications, was the leading institutions, followed by Moffitt Cancer Centre, and Memorial Sloan-Kettering Cancer Center. Authorship analysis revealed significant collaborative efforts, averaging 10.9 authors per article. Co-authorship map revealed academia-industry partnership. Temporal analysis of keywords revealed an evolution from CD19 target research (tisa-cel and axi-cel) to BCMA focused therapies (ide-cel and celta-cel). Thematic analysis showed four research themes: (1) molecular, therapeutic, and regulatory development of CAR-T constructs; (2) outcome of clinical trials; (3) economic and policy dimension of CAR-T therapy; and (4) treatment of relapsed and refractory multiple myeloma. Conclusions This study offers a translationally relevant perspective for clinicians, researchers, and policymakers, and underscores the evolving priorities in therapeutic development, access, and sustainability in precision oncology.
- 3 August 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-19
Open AccessKnowledge-map and bibliometric analysis of scientific research on FDA-approved Chimeric Antigen Receptor T cell products (2015–2024)
Background Chimeric Antigen Receptor T cell (CAR-T) therapy is a groundbreaking, personalized immunotherapy that genetically engineers patient or donor-derived T cells to recognize and eliminate cancer cells. The U.S FDA has approved six CAR-T cell products in the past decade. Objective Given their clinical success and scientific novelty, this study aimed to map the research landscape surrounding the FDA-approved CAR-T cell therapies using bibliometric and knowledge mapping analysis. Methods A comprehensive title/abstract search was conducted in Scopus database for documents published between 2015 and 2024. The search terms included generic, trade, and abbreviated names of all FDA-approved CAR-T cell products. Bibliometric indicators including average annual growth rate, citation impact, key contributors, authorship pattern, and international collaboration were assessed. Visualization maps of co-authorship and keyword co-occurrence were generated using VOSviewer. Results A total of 1163 documents were retrieved, with an average annual growth rate of 63.4%. Tisa-cel and axi-cel dominated the literature with 51.7% (n = 601) and 554 (47.6%) publications respectively. Ide-cel appeared in 152 (13.1%) publications, liso-cel in 125 (10.7%), and cilta-cel in 120 (10.3%). Brexu-cel was the least represented with 106 (9.1%) publications. The retrieved publications received 57,097 citations (mean = 49.1 citations per article; H-index = 103). Hematology and oncology-related journals were most prolific. The United States led global research output with 694 (59.7%) publications. Research output from European countries showed strong dependence on U.S.-based partnerships. Institutionally, the University of Texas MD Anderson Cancer Center, with 132 publications, was the leading institutions, followed by Moffitt Cancer Centre, and Memorial Sloan-Kettering Cancer Center. Authorship analysis revealed significant collaborative efforts, averaging 10.9 authors per article. Co-authorship map revealed academia-industry partnership. Temporal analysis of keywords revealed an evolution from CD19 target research (tisa-cel and axi-cel) to BCMA focused therapies (ide-cel and celta-cel). Thematic analysis showed four research themes: (1) molecular, therapeutic, and regulatory development of CAR-T constructs; (2) outcome of clinical trials; (3) economic and policy dimension of CAR-T therapy; and (4) treatment of relapsed and refractory multiple myeloma. Conclusions This study offers a translationally relevant perspective for clinicians, researchers, and policymakers, and underscores the evolving priorities in therapeutic development, access, and sustainability in precision oncology.
- Open Access
- 1 May 2025
- Published by SAGE Publications in Digital Health
- Vol. 11
AI-Powered histopathology slide image interpretation in oncology: A comprehensive knowledge mapping and bibliometric analysis
Objectives: To map global research on AI-driven histopathological image interpretation in oncology (2000–2024). Methodology: Scopus-based bibliometrics using Boolean queries; data exported, cleaned, and analyzed in VOSviewer. Results: The dataset included 1874 publications, surging after 2015. China (n = 561) and the United States (n = 467) led output; leading institutions included Harvard Medical School and the Chinese Academy of Sciences. Top journals were Scientific Reports, Cancers, and IEEE Access; the corpus H-index was 112. Collaboration networks intensified, especially U.S.–Asia. Keyword mapping showed four clusters: (1) deep learning for breast cancer/CNN diagnostics; (2) transfer learning/feature extraction; (3) prognostic modeling/tumor microenvironment; and (4) digital infrastructure/explainable AI. Overlay analyses traced a shift from classical machine learning to transformers and multimodal models integrating molecular and clinical data; emerging themes include semantic segmentation, self-supervised learning, and therapy-response prediction. Applications spanned breast, prostate, colorectal, head–neck, gynecologic, and gastrointestinal/liver cancers. Models primarily used whole-slide images (e.g., TCGA) and multi-omics; algorithms included CNNs, deep learning, classical machine learning, and weakly supervised approaches. Evidence ranged from proof-of-concept to multicenter validation and workflow integration; adoption remains constrained by data standardization, interpretability, and regulation. Clinically, AI improved diagnostic accuracy/efficiency and supported personalization via multi-omics. Bibliographic coupling revealed three clusters: clinical/translational journals; engineering/computational outlets; and interdisciplinary venues linking algorithmic innovation with digital pathology. Conclusions: AI histopathology is advancing toward clinical-grade deployment, propelled by collaboration and methodological innovation, yet limited by data standards, explainability, and regulatory requirements.
- 1 May 2025
- Published by SAGE Publications in Digital Health
- Vol. 11
Open AccessAI-Powered histopathology slide image interpretation in oncology: A comprehensive knowledge mapping and bibliometric analysis
Objectives: To map global research on AI-driven histopathological image interpretation in oncology (2000–2024). Methodology: Scopus-based bibliometrics using Boolean queries; data exported, cleaned, and analyzed in VOSviewer. Results: The dataset included 1874 publications, surging after 2015. China (n = 561) and the United States (n = 467) led output; leading institutions included Harvard Medical School and the Chinese Academy of Sciences. Top journals were Scientific Reports, Cancers, and IEEE Access; the corpus H-index was 112. Collaboration networks intensified, especially U.S.–Asia. Keyword mapping showed four clusters: (1) deep learning for breast cancer/CNN diagnostics; (2) transfer learning/feature extraction; (3) prognostic modeling/tumor microenvironment; and (4) digital infrastructure/explainable AI. Overlay analyses traced a shift from classical machine learning to transformers and multimodal models integrating molecular and clinical data; emerging themes include semantic segmentation, self-supervised learning, and therapy-response prediction. Applications spanned breast, prostate, colorectal, head–neck, gynecologic, and gastrointestinal/liver cancers. Models primarily used whole-slide images (e.g., TCGA) and multi-omics; algorithms included CNNs, deep learning, classical machine learning, and weakly supervised approaches. Evidence ranged from proof-of-concept to multicenter validation and workflow integration; adoption remains constrained by data standardization, interpretability, and regulation. Clinically, AI improved diagnostic accuracy/efficiency and supported personalization via multi-omics. Bibliographic coupling revealed three clusters: clinical/translational journals; engineering/computational outlets; and interdisciplinary venues linking algorithmic innovation with digital pathology. Conclusions: AI histopathology is advancing toward clinical-grade deployment, propelled by collaboration and methodological innovation, yet limited by data standards, explainability, and regulatory requirements.